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Background. The accumulation of risk factors for central retinal artery occlusion can be
seen in a single person and might be explained by the metabolic syndrome. Case report.
We presented the case of a 52-year-old man with no light perception in his right eye. The
visual loss was monocular and painless, fundoscopy showed central retinal artery occlu-
sion and the laboratory investigation showed the raised erythrocyte sedimentation rate of
105 mm/h and the raised C-reactive protein of 22 mg/l. Specific laboratory investigations
and fluorescein angiography excluded the presence of vasculitis, collagen vascular dis-
eases, hypercoagulable state and antiphospholipid syndrome. Conclusion. The patient met
all the five of the National Cholesterol Education Program (NCEP) criteria for the meta-
bolic syndrome: hypertension, abnormal lipid profile, abnormal glucose metabolism, obe-
sity and hyperuricemia. Measurement of C-reactive protein is useful for the assessment of
therapeutic systemic effect on any abnormality in the metabolic syndrome. Individual ther-
apy for all risk factors in the  metabolic syndrome is necessary to prevent complications
such as cardiovascular, retinal vascular diseases and stroke.
K e y   w o r d s : metabolic syndrome X; retinal artery;
retinal artery occlusion; visual acuity.
Background
The metabolic syndrome, or the so-called syndrome X,
or the insulin resistance syndrome is characterized by ab-
dominal obesity, diabetes, glucose intolerance, dyslipide-
mia, high blood pressure and hyperuricemia (1). According
to the National Cholesterol Education Program (NCEP)
criteria, an individual may be diagnosed to have the meta-
bolic syndrome if he/she has three or more of the following
findings: abdominal obesity, triglycerides >  1.7 mmol/l,
HDL cholesterol < 1.0 mmol/l, blood pressure > 130/85 or
antihypertensive medication and fasting glucose >  6.1
mmol/l (insulin or hypoglycemic agents) (2, 3). The results
of many studies suggest that arteriosclerosis and insulin re-
sistance share a common inflammatory basis by showing
that the raised C-reactive protein has direct harmful effects
on vessel walls (4). Furthermore, these metabolic disorders
are closely linked to each other, and thus the primary patho-
genesis of this syndrome is difficult to determine in each
patient. It also remains to be determined which metabolic
disorders should be the primary therapeutic targets to pre-
vent cardiovascular diseases (CVD) and stroke, and which
metabolic disorders should be monitored to follow thera-
peutic effects (2, 5, 6).
Central retinal artery occlusion (CRAO) is one of the
most sudden and dramatic events seen by the ophthalmolo-
gist and was described as early as in 1859 (7). Patients usu-
ally present with a sudden painless loss of vision. The ap-
pearance of a cherry-red spot in the fundus was the main
characteristic (8). The cherry-red spot appears because soon
after the obstruction of the blood flow to the inner retina,
the normally transparent retina becomes opaque and blocks
the brownish-red color from the underlying choroid, which
is still supplied by blood. Because the retina overlying the
foveola is relatively thin, however, the normal color of the
choroid is still visible in this area (9). It is not known howСтрана 936 ВОЈНОСАНИТЕТСКИ ПРЕГЛЕД Број 12
long this cherry-red spot takes to appear, but in a primate
model, it appears as early as 30 minutes after the obstruc-
tion (10). The difference in the etiology of CRAO depends
on the age of patients presenting with an obstruction. The
CRAO in patients 30 years of age or younger tends to be as-
sociated with migraine, coagulation disorders, intraocular
abnormalities, and trauma (11).
Possible risk factors for the development of CRAO are
arteriosclerosis, chronic atrial fibrillation, congestive heart
failure, cerebrovascular accident, systemic hypertension,
myocardial infarction, diabetes mellitus, primary open angle
glaucoma and rheumatic heart diseases (10, 12).
Case report
We presented the case of a 52-year-old man who sud-
denly observed severe painless visual loss with no light per-
ception in his right eye. Our assessment showed that the
best corrected visual acuity in the left eye was 6/6 by Snel-
len chart. Intraocular pressure was 16 mm Hg in both eyes
measured by applanation tonometry. Both anterior segments
were normal. An afferent pupil defect was present in the
right eye.
The CRAO diagnose was based on the abrupt visual
loss accompanied by one or more of the following signs as
observed by slit lamp biomicroscopy with a +78 diopter
lens, fundus photography and fluorescein angiography
(FA): sluggish, thinned retinal artery flow; the fragmenta-
tion of the blood column in retinal arterioles; retinal opaci-
fication combined with sluggish retinal blood flow; and the
presence of a cherry red spot (Figures 1−2). These findings
were compared with the fellow uncompromised eye. The
left fundus was normal.
Standard laboratory investigations revealed: the raised
erythrocyte sedimentation rate 105 mm/h, the raised C-
reactive protein 22 mg/l, and fibrinogen 6 g/l. The serum
uric acid level was high, 650 μmol/l (normal < 420 μmol/l).
The full blood count (red cell count 4.03, hemoglobin 11.3
g/dl, packed cell volume (PCV) 0.33, platelet count 298,
and white blood count 6.6), prothrombin time 89% and the
activated partial thromboplastin time 29 s, serum creatinine
144  μmol/l, serum urea 11.9 mmol/l, fasting glucose
4.55−6.9 mmol/l, HbA1c 7.6%, serum lipid levels: total
cholesterol 7.9 mmol/l, high-density lipoprotein (HDL) 1.04
mmol/l, and triglycerides 3.98 mmol/l. The presence of
rheumatoid factor antibodies, antinuclear antibodies, anti-
neutrophil cytoplasmatic antibodies, immune complexes,
antiphospholipid antibody and lupus anticoagulans were
also analyzed. They were negative.
The patient had been only under hypertension treat-
ment since 1993. During cardiologic examination, chest ra-
diography was normal, and no anomaly of cardiac rhythm
was found by Holter monitoring. Normal atrial and ven-
tricular volumes, normal valvular function and normal
coronary arteries (< 10% stenosis) were found on echocar-
diography. A color Doppler scan of the carotid arteries
showed bilateral stenosis of 30%. A urine test revealed mi-
crohematuria with urate crystals. We found nephrolithiasis
of the right side by renal ultrasonography.
Fig. 1 − Fundus photograph of the right eye show central reti-
nal artery occlusion (cherry-red spot)
Fig. 2 − The early phase (23 s) of the fluorescein angiogram of
the right eye shows complete failure of dye to enter the retinal
circulation and retrograde filling close to the optic disc
Discussion
In this patient we could change the traditional attitude
toward making a diagnosis by considering the examination
findings first and then the history of a disease in an attempt
to come to a differential diagnosis. Our third key point on
examination allowed us to point out precisely the giant cellБрој 12 ВОЈНОСАНИТЕТСКИ ПРЕГЛЕД Страна 937
arteritis (GCA). Visual loss was at first monocular and
painless, then fundoscopy revealed CRAO, and then the
laboratory investigation showed the raised ESR of 105
mm/h (normal 33 mm/h), and the raised CRP of 22 mg/l
(normal 6 mg/l). We had those results available within the 2
hours. There was a high index of suspicion to GCA. The in-
cidence of CRAO in GCA given in the literature was be-
tween 2% and 18% (13, 14). GCA is a potentially blinding
disease, and its early diagnosis is the key to prevent the
blindness in the fellow eye with the megadose therapy
(1 000 mg prednisone i.v.) (14). To confirm a diagnosis, our
patient undervent biopsy of the right temporal artery imme-
diately, but histopathological examination was negative.
The nonspecific markers of immune system activation
(CRP, ESR) were raised and it is our practice to search for
anticardiolipin antibodies in cases of the clinical and
fluorangiagraphic evidence of retinal vasculitis, vascular
thrombosis, central retinal vein occlusion and CRAO. The
prevalence of CRAO in antiphospholipid syndrome is un-
certain, and is always assessed in relation to the associated
syndrome (systemic lupus erythematosus) between 7% and
9% with red eye, diplopia and headache (15, 16). Specific
laboratory investigations and FA showed that vasculitis,
collagen vascular diseases, hypercoagulable state, and anti-
phospholipid syndrome were excluded.
Arteriosclerosis is probably the most commonly asso-
ciated systemic condition with CRAO. In some cases, a
cause of CRAO is relatively clear, such as a visible embo-
lus. In other cases, however, especially those associated
with systemic disorders such as diabetes, hypertension,
CVD, the association is less clear (10). O'Farrell et al., (17)
found no difference between stenosis in the ipsilateral and
the contralateral carotid artery. This suggests that the cause
of retinal artery occlusions may not be carotid artery steno-
sis  − it may be simply associated with these occlusions.
Merchut et al. (18) found no relation between the types of
arterial occlusion branch or central, and the type of under-
lying carotid artery disease. Wijman et al. (19) found a high
grade internal carotid stenosis of 70% or more in 73% of the
patients with retinal ischemia that included transient ische-
mic attacks (TIAs), and arterial occlusions, both acute and
chronic. Diabetes mellitus and CVD are probably the next
two most common associated conditions (20, 21).
According to the recent literature, the most common
risk factors for CRAO are present in the metabolic syn-
drome. The patient had all the five NCEP criteria for meta-
bolic syndrome: hypertension, abnormal lipid profile, ab-
normal glucose metabolism, obesity and hyperuricemia.
Each abnormality involved in the metabolic syndrome with
the raised proinflamatory marker levels (CRP, fibrinogen) is
also a classic risk factor for CVD and stroke (1−3).
Conclusion
Although there have been numerous clinical and ex-
perimental studies of the pathophysiology of CRAO, the
disease still has multifactorial causes and relatively poor
visual prognosis (blindness). Each abnormality involved in
the metabolic syndrome is also a classic risk factor for the
retinal obstructive diseases and CVD. Accumulation of such
risk factors in a single person, younger than 55 years, can
be the result of two mechanisms: the coincidence or the
clustering. Unfortanately, there is no therapeutic strategy to
treat this condition. The measurement of CRP is useful for
the assessment of therapeutic systemic effect on each ab-
normality in the metabolic syndrome. Individual therapy is
necessary to reveal any risk factor and to prevent complica-
tions such as CVD, stroke and retinal vascular diseases.
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Apstrakt
Kosanović-Jaković N, Petrović L, Risimić D, Milenković S, Matić D. Vojnosanit
Pregl 2005; 62(12): 935−938.
METABOLIČKI SINDROM I OKLUZIJA ARTERIJE CENTRALIS RETINE
Uvod. Prisustvo svih vodećih faktora rizika za okluziju arterije centralis retine mogu
se videti kod jednog bolesnika u sklopu metaboličkog sindroma. Prikaz bolesnika.
Prikazujemo slučaj 52-godišnjeg muškarca bez osećaja svetla na desnom oku.
Gubitak oštrine vida bio je monokularan i bezbolan, fundoskopija je pokazala prisu-
stvo okluzije arterije centralis retine, a laboratorijski nalazi su ukazali na povišenu
sedimentaciju eritrocita od 105 mm/h i povišen C-reaktivni protein od 22 mg/l. Spe-
cifični laboratorijski nalazi, kao i fluoresceinska angiografija isključili su postojanje
vaskulitisa, kolagenih vaskularnih bolesti, stanja hiperkoagulabilnosti i antifosfolipi-
dnog sindroma. Zaključak. Bolesnik ima svih pet Nacionalni holesterol obrazovni
program (NHOP) kriterijuma za postavljanje dijagnoze metaboličkog sindroma: hi-
pertenzija, abnormalni lipidni status, poremećen metabolizam glukoze, gojaznost i
hiperurikemija. Praćenje vrednosti C-reaktivnog proteina korisno je za praćenje
efekta sistemske terapije na svaki pojedinačni poremećaj u metaboličkom sindromu
kako bi se preveniralo nastajanje komplikacija poput kardiovaskularnih bolesti, vas-
kularnih bolesti retine i cerebrovaskularnog insulta.
Kl juč ne reč i : metabolični sindrom X; a. centralis retinae;
okluzija; vid, oštrina.
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